Peer coaches aim to close genetic testing gap for black men with prostate cancer
NCT ID NCT05627219
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a network of peer genetic coaches can help African American men with metastatic prostate cancer overcome barriers to genetic testing. The coaches are trained to provide education, address concerns, and guide men through the testing process. The goal is to see if this approach is feasible and improves access to genetic counseling and testing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Peer genetic coaching (behavioral intervention)
- What this could lead to
- If successful, this approach could improve genetic testing rates and reduce healthcare disparities for African American men with prostate cancer.
- What could go wrong
- This is a small, early feasibility study with only 30 participants, so results may not apply broadly. It focuses on awareness and navigation, not direct treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Men who have experience with both prostate cancer (PCA) and genetic counseling and testing, as well as peer education or navigation experience. African American men with a history of prostate cancer or with a strong family history of prostate cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * AIM 1: Are 18 years old or older * AIM 1: Are able to read and speak English comfortably * AIM 1: Men who have experience with both prostate cancer (PCA) and genetic counseling and testing will be a priority for training, as well as men who have considerable peer education or navigation experience * AIM 2: Are 18 years old or older * AIM 2: Are African American * AIM 2: Are able to read and speak English comfortably * AIM 2: Men who meet any one of the following criteria: (1) metastatic prostate cancer; (2) prostate cancer with high-risk features (T3 or higher, Gleason 8 or higher, node positive disease); (3) with or without a diagnosis of prostate cancer with strong family history (2 or more first-degree or second-degree relatives) with prostate cancer (particularly metastatic prostate cancer or died from prostate cancer), breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer Exclusion Criteria: * Patients that do not meet the inclusion criteria * Children under the age of 18 * Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic prostate carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI-Guided radiation zero in on prostate tumors with fewer side effects?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Hormone therapy plus precision radiation aims to crush prostate cancer early
- Double-Dose precision: new combo radiation aims to shrink prostate tumors faster
- Freezing or heating prostate tumors: a targeted alternative to surgery?